Genetic polymorphism of merozoite surface protein-3 in Myanmar *Plasmodium falciparum* field isolates

Hương Giang Lê¹,²†, Thị Lam Thái¹,²†, Jung-Mi Kang¹,², Jinyoung Lee³, Mya Moe⁴, Túan Cường Võ¹,², Haung Naw¹,², Moe Kyaw Myint⁴, Zaw Than Htun⁴, Tong-Soo Kim³, Ho-Joon Shin⁵ and Byoung-Kuk Na¹,²*

### Abstract

**Background:** *Plasmodium falciparum* merozoite surface protein-3 (PfMSP-3) is a target of naturally acquired immunity against *P. falciparum* infection and is a promising vaccine candidate because of its critical role in the erythrocyte invasion of the parasite. Understanding the genetic diversity of pfmsp-3 is important for recognizing genetic nature and evolutionary aspect of the gene in the natural *P. falciparum* population and for designing an effective vaccine based on the antigen.

**Methods:** Blood samples collected from *P. falciparum*-infected patients in Naung Cho and Pyin Oo Lwin, Myanmar, in 2015 were used in this study. The pfmsp-3 was amplified by polymerase chain reaction, cloned, and sequenced. Genetic polymorphism and natural selection of Myanmar pfmsp-3 were analysed using the programs DNASTAR, MEGA6, and DnaSP 5.10.00. Genetic diversity and natural selection of the global pfmsp-3 were also comparatively analysed.

**Results:** Myanmar pfmsp-3 displayed 2 different alleles, 3D7 and K1. The 3D7 allelic type was predominant in the population, but genetic polymorphism was less diverse than for the K1 allelic type. Polymorphic characters in both allelic types were caused by amino acid substitutions, insertions, and deletions. Amino acid substitutions were mainly occurred at the alanine heptad repeat domains, whereas most insertions and deletions were found at the glutamate rich domain. Overall patterns of amino acid polymorphisms detected in Myanmar pfmsp-3 were similar in the global pfmsp-3 population, but novel amino acid changes were observed in Myanmar pfmsp-3 with low frequencies. Complicated patterns of natural selection and recombination events were predicted in the global pfmsp-3, which may act as major driving forces to maintain and generate genetic diversity of the global pfmsp-3 population.

**Conclusion:** Global pfmsp-3 revealed genetic polymorphisms, suggesting that the functional and structural consequences of the polymorphisms should be considered in designing a vaccine based on PfMSP-3. Further examination of genetic diversity of pfmsp-3 in the global *P. falciparum* population is necessary to gain in-depth insight for the population structure and evolutionary aspect of global pfmsp-3.

**Keywords:** *Plasmodium falciparum*, Merozoite surface protein-3, Genetic diversity, Natural selection, Myanmar

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
44–48 kDa via removal of the N-terminal region in the parasitophorous vacuole [1, 2]. PfMSP-3 plays critical roles in erythrocyte binding of the parasite and protecting the parasite against toxic haem that is inevitably produced by haemoglobin hydrolysis [3]. It is also reported that PfMSP-3 is a target of host immune responses. PfMSP-3 induced naturally acquired immunity by producing antibodies that mediate antibody-dependent cellular inhibition of the parasite [3]. Immunization of PfMSP-3 induced protective immunity in animal models [4, 5]. Moreover, anti-PfMSP-3 antibodies suppressed the growth of *P. falciparum* in vitro in the presence of blood monocytes [2, 6]. Vaccines formulated with PfMSP-3 alone or in combination with other vaccine candidate antigens have been designed and their effectiveness in inducing production of cytophilic antibodies that could inhibit *P. falciparum* erythrocytic growth has been evaluated [7, 8]. GMZ2, the vaccine formulated with a chimeric antigen constructed with the C-terminal region of PfMSP-3 and the N-terminal region of glutamate rich protein (GLURP), was well tolerated and immunogenic, and elicited high levels of functional antibodies suppressing multiplication of the parasite [9–12]. The essential biological functions of PfMSP-3 during parasite survival and the accumulated evidence that specific antibodies for PfMSP-3 are effective in parasite killing and protection against clinical malaria suggest that this protein as a promising vaccine candidate antigen.

Genetic polymorphisms in vaccine candidate antigens of *P. falciparum* are great hurdles to develop effective vaccines since they could generate a variant-specific immune response that is less effective against parasites with other genetic variants. Like other vaccine candidate antigens, the genetic diversity of *pfmsp*-3 was also reported in natural parasite populations [13–16]. The *pfmsp*-3 consists of 3 separated regions: the N-terminal region containing four alanine heptad repeats (AHR) having the AXX-AXXX motif, the glutamate rich domain, and the C-terminal region containing a leucine zipper motif [17–20]. The gene is classified into 2 different alleles, 3D7 and K1, based on the difference in size of the AHR at the N-terminal region [17]. It has been proposed that the N-terminal region was polymorphic, whereas the C-terminal region was relatively well conserved in *P. falciparum* populations in several countries including Iran [14], Thailand [13, 15], Cameroon, Republic of Congo, Burkina Faso, Ghana, and Senegal [16]. In-depth understanding of the population genetic structure of *pfmsp*-3 in the natural *P. falciparum* population is important not only for evaluating the genetic nature of the vaccine candidate antigen, but also for advancing effective vaccine development.

However, compared to other vaccine candidate antigens, fewer studies have been done to understand the genetic polymorphisms of *pfmsp*-3 in the natural *P. falciparum* population. In this study, the genetic diversity and natural selection of *pfmsp*-3 in Myanmar *P. falciparum* isolates were analysed. Comparative analysis of global *pfmsp*-3 was also performed to gain in-depth understanding of the genetic make-up of the gene in the global *P. falciparum* population.

Methods

Blood samples and extraction of genomic DNA

Seventy-two blood samples were obtained from *P. falciparum* infected symptomatic patients who live in villages located in Naung Cho and Pyin Oo Lwin, Myanmar in 2015 (Additional file 1: Fig. S1). *P. falciparum* infection was confirmed by Giemsa-stained thick and thin blood smear examination. All *P. falciparum* positive samples were further confirmed by polymerase chain reaction (PCR) targeting 18S ribosomal RNA (rRNA) gene [21]. Finger-prick blood samples were collected from the patients prior to drug treatment, air-dried, and stored in individual sealed plastic bag at ambient temperature until use. Genomic DNA was extracted from the blood filters using the QIAamp DNA Blood Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. Written informed consent was obtained from all patients before blood collection. The study protocol was approved by either the Ethics committee of the Ministry of Health, Myanmar (97/Ethics 2015) and the Biomedical Research Ethics Review Board of Inha University School of Medicine, Republic of Korea (INHA 15-013).

Amplification and sequencing analysis of *pfmsp*-3

The full-length *pfmsp*-3 was amplified by a nested PCR method. The primers used in this study were designed as described previously [13]. The thermal cycling parameters for primary and nested PCRs were as follows: one cycle of initial denaturation at 95 °C for 5 min, 25 cycles of 94 °C for 1 min, annealing at 57 °C for 2 min and extension at 72 °C for 2 min, followed by a final extension at 72 °C for 5 min. Ex Taq DNA polymerase (Takara, Otsu, Japan) with proof-reading activity was used in all PCR amplification steps to minimize the nucleotide mis-incorporation. PCR products were resolved on a 1.2% agarose gel, and were visualized under ultraviolet (UV). Each PCR product was purified from the gel, and cloned into the T&G vector (Real Biotech Corporation, Banqiao City, Taiwan). Ligation mixture was transformed into *Escherichia coli* DH5α competent cells, and positive clones with appropriate insert were selected by colony PCR. The nucleotide sequence of cloned insert was analysed by automatic DNA sequencing with M13 forward and M13 reverse primers. Plasmids from at least two independent clones from each transformation mixture.
were sequenced in both directions to verify the sequence accuracy. The nucleotide sequences reported in this study have been deposited in the GenBank database under the accession numbers MN787600-MN787671.

Analyses of sequence polymorphism and genetic diversity of Myanmar pfmsp-3

The nucleotide and deduced amino acid sequences of pfmsp-3 were analysed using EditSeq and SeqMan in the DNASTAR package (DNASTAR, Madison, WI, USA). The pfmsp-3 sequences of 3D7 (XM_001347593) and K1 (U08851) were used as reference sequences. The value of singleton variable sites, parsimony informative sites, total number of mutations, segregating sites (S), average number of singleton variable sites, parsimony informative sites, total number of mutations, segregating sites (S), average number of pair-wise nucleotide difference (K), haplotype diversity (Hd), and nucleotide diversity (π) were calculated using DnaSP version 5.10.00 [22]. The π was also measured on sliding window plot of 10 bases with a step size of 5 bp to estimate the stepwise diversity across the sequences. The rate of synonymous (dS) and non-synonymous (dN) substitutions were estimated and compared by the Z-test (P<0.05) in order to test the null hypothesis of strict neutrality of pfmsp-3 in MEGA6 program [23] using the Nei and Gojobori's method [24] with the Juke and Cantor correction (1000 bootstrap replications). Tajima's D test [25], and Fu and Li’s D and F statistics [26] were performed to evaluate the neutral theory of natural selection using DnaSP version 5.10.00 [22]. The Tajima's D values were also calculated on sliding window plot of 10 bases with a step size 5 bp to estimate the natural selection parameter across the gene.

Genetic diversity of pfmsp-3 among the global P. falciparum isolates

The genetic diversity of global pfmsp-3 from different P. falciparum populations was analysed. The pfmsp-3 sequences included in this study were from Thailand (AM161544-AM161593), India (HM568669-HM568724), Kenya (KU527019-KU527058), and Nigeria (AM161594-AM161644). These sequences covered full-length or partial of pfmsp-3. Genetic polymorphism and tests of neutrality of each population were analysed or calculated using DNASTAR package, DnaSP version 5.10.00 [22] and MEGA6 [23] as describe above. A logo plot was constructed for each pfmsp-3 population to analyse the polymorphic patterns in the B cell epitopes using the WebLogo program (https://weblogo.berkeley.edu/logo.cgi).

Results

Sequence polymorphisms of Myanmar pfmsp-3

Seventy-two pfmsp-3 were successfully amplified from Myanmar P. falciparum isolates. Sequence alignment analysis of the sequences suggested that they were classified into 2 allelic types, 3D7 type (n = 43) and K1 type (n = 29). For the 3D7 allelic types, 164 single nucleotide polymorphisms (SNPs) were identified at 87 polymorphic sites, in which 122 SNPs were non-synonymous mutations, resulting in amino acid substitutions at 49 positions. Four amino acid positions showed tri-morphic changes (F12L/S, D142E/G, Y192C/H, and D278E/M) and the others were di-morphic amino acid changes. The most predominant amino acid substitutions identified in Myanmar pfmsp-3 were L68S and D278E/M, which accounted for 90.7% and 58.1% in frequency, respectively. The other amino acid changes occurred at very low proportions. Amino acid changes at 25 positions (G71S, E98G, T117A, D142E/G, A163V, Y192C/H, K236E, E245G, E249G, E253K, S261T, D263E, E267V, E274R, E275K, E276K, N277K, D278M, K281E, K285T, N311D, K331E, G332E, Q335R, and V344I) were novel ones that have not been reported previously. The glutamate rich domain of Myanmar pfmsp-3 was varied because of different repeat numbers of glutamate residues, ranging from 4 to 8 repeats. Deletions of E271 and/or E272 were identified in 12 distinct haplotypes and insertion of 2 additional glutamates was found in haplotype 26. Based on these polymorphic patterns, the 3D7 allelic types of Myanmar pfmsp-3 were further classified into 31 distinct haplotypes, in which haplotype 9 had the highest prevalence (23.3%) (Fig. 1). In the K1 allelic types, a total of 25 distinct haplotypes were identified. Haplotype 21 was the most prevalent, accounting for 17.2%. Sequence analysis revealed that there were 944 SNPs at 117 polymorphic sites, among which 576 SNPs were non-synonymous ones leading to amino acid substitutions at 75 positions. Sixty-nine di-morphic and 6 tri-morphic (P72A/S, T81C/S, K110N/Q, Q114D/E, K188Q/R, A352T/V) amino acid changes were found. High frequency of a glutamate (E) insertion at position 79 was identified at AHR domains. Insertions of 13 amino acids (ETEEEELEKNEE) and 1–3 glutamates (E) were also detected at positions 280 and 298 in the glutamate rich domain, respectively. Amino acid deletions at 6 positions (G169, E301, T81C/S, K304, and K305) were also found in the K1 allelic types of Myanmar pfmsp-3 (Fig. 2).

Sequence polymorphism and genetic diversity of global pfmsp-3

Comparative analysis of genetic polymorphism of pfmsp-3 from Myanmar and other different geographical areas was performed. Given the partial sequence information of pfmsp-3 from other global populations, analysis focused on the 3 regions corresponding to AHR, the glutamate rich domain and the leucine zipper domain. For 3D7 allelic types, most amino acid polymorphisms
were accumulated at glutamate rich domains, but the frequencies were different by country (Fig. 3). The deletion of E272 (E272-) and an amino acid change (D280E) were found in all analysed populations. Insertions of 1 to 3 glutamate residues at the position of 272 (E272+, E272++, and E272+++ ) were more prevalent in African pfmsp-3 than in Asian pfmsp-3. The AHR and leucine zipper domains were relatively well conserved in 3D7 allelic types of global pfmsp-3. Amino acid changes at 9 positions were identified in AHR domains of global pfmsp-3, most of them only in Myanmar pfmsp-3. Only 2 amino acid changes (A103S and K164E) were found in Thailand and Kenya pfmsp-3. The five amino acid substitutions (N311D, K331E, G332E, Q335R, and V344I) in the leucine zipper domain were detected only in Myanmar pfmsp-3. Polymorphic patterns of amino acid changes were more diverse and greater in global K1 allelic types (Fig. 4). Most amino acid changes detected at AHR domains were shared by the global pfmsp-3 population with high frequencies. Only five amino acid substitutions, G75I, T81C, S98F, T165A, and K188R, were uniquely identified in Myanmar pfmsp-3. Although the

---

**Fig. 1** Sequence polymorphisms of 3D7 allelic types of *Myanmar pfmsp-3*. A total of 31 haplotypes of 3D7 allelic types were detected in Myanmar pfmsp-3. The dots present amino acid residues identical to the reference sequence of 3D7 (XM_001347593). Dashes are gaps introduced to maximize the alignment. Numbers above the alignment are amino acid positions with reference to the 3D7 sequence. The di-morphic and tri-morphic amino acid changes at particular positions are shaded by blue and red, respectively. The insertion found in Myanmar pfmsp-3 is marked by green. The number of each haplotype found in Myanmar pfmsp-3 is indicated at right.
Overall patterns of amino acid polymorphisms identified in global pfmsp-3 were similar, the frequencies of A112S, Q114E, Q117E, S119A, D121E, E123V, K124M, and E130K were relatively higher in Asian pfmsp-3 than in African pfmsp-3. The glutamate rich domain also showed polymorphic patterns in global pfmsp-3. Insertions of glutamate (E) at position 79, 13 amino acids (ETEEEELEEKNEE) at position 280, and glutamate (E) at the position 298 were found in pfmsp-3 from Thailand, Kenya, and Nigeria. Deletion of glutamate (E) at position 297 was also identified in pfmsp-3 from Kenya and Nigeria. Meanwhile, the leucine zipper domain was well-conserved in global pfmsp-3. Only 5 minor amino acid changes (N335S, N336S, T350A, A352T, and A352V) were uniquely identified in Myanmar pfmsp-3. Polymorphic patterns of the B-cell epitopes of 3D7 allelic types of global pfmsp-3 were analysed. The amino acid residues constructing the B-cell epitopes were tightly conserved in global pfmsp-3 allelic types (Fig. 5). However, di-morphic and tri-morphic amino acid changes at the corresponding residues were detected in Myanmar pfmsp-3.

Genetic diversity and natural selection of Myanmar pfmsp-3

The genetic diversity and tests of neutrality of Myanmar pfmsp-3 were analysed. The average number of nucleotide differences (K) for 3D7 and K1 allelic types were 5.30 and 33.22, respectively. The 3D7 and K1 allelic types showed similar values of haplotype diversity (Hd, 0.990±0.009 for 3D7 and 0.990±0.013 for K1), but nucleotide diversity (π) of K1 allelic types (0.0297±0.0019) was greater than that for 3D7 allelic types (0.0050±0.0009) (Table 1). The sliding window plot of π across Myanmar pfmsp-3 revealed that the highest values of π were identified at AHR domains in the K1 allelic type. In contrast, the highest values of π were detected at the glutamate rich domain for the 3D7 type. The leucine zipper domains showed low values of π in both allelic types of Myanmar pfmsp-3 (Fig. 6a). The dN–dS values of Myanmar pfmsp-3 were negative for both 3D7 (−0.007±0.002) and K1 (−0.016±0.009), suggesting that both allelic types of Myanmar pfmsp-3 were affected by negative natural selection. The value of Tajima’s D for the 3D7 allelic types
was negative (−2.692, P<0.001), suggesting that 3D7 allelic types of Myanmar Pfmsp-3 were under purifying selection. Meanwhile, the value was positive for the K1 allelic type (0.373, P>0.1), implying that the K1 type was under balancing selection (Table 1). The sliding window plot analysis of Tajima's D across Myanmar Pfmsp-3 also indicated that the values were negative across the entire gene for the 3D7 allelic types, whereas positive values of Tajima’s D were predicted at AHR domains and the leucine rich region of K1 allelic types (Fig. 6b).

Genetic diversity and natural selection of global Pfmsp-3
Influence of natural selection on the genetic diversity of the global Pfmsp-3 populations was analysed. Nucleotide diversity and patterns of natural selection predicted in 3D7 and K1 allelic types were different by country (Table 1). In the 3D7 allelic types, the values of nucleotide diversity (π) were similar for the Pfmsp-3 of each country, ranging from 0.0030 to 0.0050. The dN–dS value was negative for all countries analysed, indicating that negative natural selection may occur in global Pfmsp-3. However, the value of Tajima’s D was different by country: negative for Myanmar and Kenya, but positive for Nigeria and Thailand. The values of Fu and Li’s D and F for each country also showed a similar trend of negative or positive values. Meanwhile, more complex patterns of natural selection were predicted in K1 allelic types (Table 1). The values of nucleotide diversity (π) of K1 allelic types were greater than those of 3D7 allelic types in all countries analysed. The values ranged from 0.0230 to 0.0420. The value of dN–dS was positive in Kenya, but in other countries including Myanmar, Nigeria, and Thailand was negative. Unlike the 3D7 allelic types, the values of Tajima’s D of all countries were positive, indicating they were under balancing selection. The values of Fu and Li’s D and F were also positive in all three countries except for Myanmar. These collectively suggested that the overall genetic diversity in the K1 allelic types was greater than in the 3D7 allelic types in global Pfmsp-3. Both allelic types of global Pfmsp-3 may be affected by natural selection, but the direction of natural selection differed by country.

Linkage disequilibrium and recombination events in Myanmar Pfmsp-3
The value for the minimum number of recombination events between adjacent polymorphic sites (Rm) for the 3D7 allelic types of Myanmar Pfmsp-3 was 1 (Table 2). Potential recombination sites were predicted at the positions between 203 and 906. In the K1 allelic types, the Rm value was 10, in which recombination events were predicted at the positions 121-205, 219-231, 231-333, 345-387, 420-437, 441-505, 505-515, 563-571, 571-587, and 657-1026 (Table 2). The LD index R² plots for both 3D7 and K1 allelic types of Myanmar Pfmsp-3 declined across the analysed regions, suggesting that intragenic recombination could be a factor contributing to the genetic diversity of Pfmsp-3 found in Myanmar P. falciparum population (Fig. 7).

Discussion
PfMSP-3 is one of the leading vaccine candidates for malaria vaccine development, but its genetic makeup and evolutionary aspect in the global P. falciparum population are less understood that are other major vaccine candidate antigens, such as MSP-1, MSP-2, apical membrane antigen-1 (AMA-1), and circumsporozoite surface protein (CSP) of the parasite. In this study, genetic diversity and natural selection of Myanmar Pfmsp-3 were analysed. Two allelic types of Pfmsp-3, 3D7 and K1, were identified in Myanmar Pfmsp-3 with the predominance of the 3D7
allelic type (59.7%). This is consistent with other reports that 3D7 allelic types are more prevalent in Peru [27], East Republic of Congo and Burkina Faso [16], and the Thailand-Laos border [15]. Meanwhile, the recombinant allelic type, which was reported in pfmsp-3 from Iran and Africa countries with a very low frequency [14, 16], was not identified in Myanmar pfmsp-3. The lack of a recombinant allelic type may result from the large sequence difference between the two dimorphic alleles, which impedes recombination during meiosis. Otherwise, the sequence dimorphism among pfmsp-3 may be strictly maintained in the population by balancing selection [28, 29]. However, recombination between and among the same allelic type of Myanmar pfmsp-3 is likely to occur, considering the Rm value in each allelic type. Particularly, the K1 allelic type of Myanmar pfmsp-3 revealed many recombination events, indicating that active intragenic recombination is occurring in the population.

Both 3D7 and K1 allelic types of Myanmar pfmsp-3 revealed polymorphic characteristics caused by amino acid substitutions, insertions, and deletions. Amino acid substitutions mainly occurred at the AHR domain in both allelic types of Myanmar pfmsp-3. Meanwhile, insertions and deletions were found at the glutamate rich domain. The major amino acid substitutions and insertions/deletions found in both allelic types of Myanmar pfmsp-3

---

Fig. 4 Comparison of amino acid polymorphism of K1 allelic types of pfmsp-3 between Myanmar and different geographical areas. Positions and frequencies of amino acid changes found in pfmsp-3 of Myanmar and other countries were compared. Each domain is presented by different color bar; alanine heptad repeat domains (black), glutamate rich domain (orange), and leucine zipper domain (green). The dotted red bar in India pfmsp-3 means missed sequence. The G169- and E297- represent deletion of an amino acid in the corresponding site. E272ETEEEELEEKNNE++ means insertion in the position. The 298E++, 298E+++, and 298E++++ mean the numbers of inserted glutamate residues at the positions with 1, 2, and 3, respectively.
In particular, the regions corresponding to amino acids B-cell epitopes is a target of naturally acquired immunity. Demonstrated yet and therefore further study to understand this phenomenon would be necessary. The N-terminal region of pfmsp 3D7 allelic types were also well conserved in the global primary structure of PfMSP-3 [19], were highly conserved including the ARH. The B-cell epitopes of 3D7 allelic types were shared by global pfmsp-3, but their frequencies differed by geographical origin. Interestingly, novel amino acid changes that were not reported previously for either allelic type of Myanmar pfmsp-3, which renders genetic diversity of Myanmar pfmsp-3 more complex; 31 and 25 haplotypes for the 3D7 and K1 allelic types, respectively. Although incidence of malaria has been remarkably decreased in Myanmar in recent years [30], it seems likely that much genetic diversity is still maintained in Myanmar P. falciparum population. Regardless of the declining population in recent years, substantial levels of genetic heterogeneities in pfmsp-1, pfmsp-2, pfama-1, and pfpsp have been reported in the Myanmar P. falciparum population [31–34]. The reason for this is not clearly demonstrated yet and therefore further study to understand this phenomenon would be necessary.

Despite different rates of amino acid changes and insertions/deletions in pfmsp-3 from each country, the overall patterns of amino acid polymorphisms were similar in the global pfmsp-3 population. Major amino acid changes and insertions/deletions found in both 3D7 and K1 allelic types were observed at the AHR and glutamate rich domains. The repeats of the AXXAXXX motif, which plays a role in maintaining and forming an α-helical secondary structure of PfMSP-3 [19], were highly conserved in global pfmsp-3 regardless of diversity within and flanking the ARH. The B-cell epitopes of 3D7 allelic types were also well conserved in the global pfmsp-3 population. The N-terminal region of pfmsp-3 including the B-cell epitopes is a target of naturally acquired immunity. In particular, the regions corresponding to amino acids 21 to 238 not only is an important immunogen to produce a protective immune response but also is involved in the interaction with PfMSP-1 [35]. The prevalence of opsonizing antibodies against the N-terminal region rather than the C-terminal region of pfmsp-3 also suggests a critical role of the N-terminal region as a target of opsonizing antibodies. Therefore, the N-terminal region of pfmsp-3 may represent an attractive candidate for formulation of a PfMSP-3-based vaccine. Meanwhile, the leucine zipper domain was relatively well conserved in global pfmsp-3. The limited polymorphic pattern of the C-terminal region, especially in the leucine zipper domain, may result from its crucial function in the formation of protein oligomerization [3, 36]. Moreover, the C-terminal region of pfmsp-3 plays an essential function in the invasion process of merozoite by mediating specific binding with erythrocytes [37].

The dN–dS values for 3D7 allelic types of global pfmsp-3 were negative, implying that negative selection might act in the gene. Meanwhile, the values of Tajima’s D and Fu and Li’s D and F revealed complicated patterns that were different by country. These suggest that a complicated natural selection may act on 3D7 allelic types of the global pfmsp-3, in which either positive selection or purifying selection might have occurred in the population, depending on the geographical origin. As expected, overall nucleotide diversity in K1 allelic types was greater than that in 3D7 allelic types in the global isolates. The positive values of Tajima’s D indicated that K1 allelic types of global pfmsp-3 evolved under balancing selection. Amino acid substitutions, insertion or deletions may be the main pressure to generate genetic diversity of the allelic types. High recombination parameters also support the notion that recombination may be one of a force contributing to generate genetic diversity of K1 allelic types of global pfmsp-3.

**Conclusion**

Myanmar pfmsp-3 showed genetic polymorphisms. Two different alleles, 3D7 and K1, were detected in Myanmar pfmsp-3, with a higher prevalence of 3D7 allelic types. Overall patterns of nucleotide diversity and distributions of amino acid changes and insertions/deletions found in Myanmar pfmsp-3 were similar to those from global pfmsp-3, even though minute regional differences were also identified between and among each population. Complicated patterns of natural selection and recombination events were predicted in the global pfmsp-3, which may act as major driving forces to maintain and generate genetic diversity of the global pfmsp-3 population. These results suggest that the functional
### Table 1 Genetic polymorphism and tests of neutrality of pfmsp-3 in global P. falciparum isolates

| Country   | Singleton variable sites | Parsimony informative sites | Total no. of mutations | S    | K    | H    | Hd ± SD | π ± SD | dN–dS | Tajima's D (P value) | Fu and Li's D (P value) | Fu and Li's F (P value) |
|-----------|--------------------------|-----------------------------|------------------------|------|------|------|---------|--------|-------|----------------------|-------------------------|-------------------------|
| 3D7       |                          |                             |                        |      |      |      |         |        |       |                      |                         |                         |
| Myanmar   | 77                       | 10                          | 90                     | 87   | 5.30 | 37   | 0.990 ± 0.009 | 0.0050 ± 0.0006 | − 0.007 ± 0.002 | − 2.692 (P < 0.001) | − 5.616 (P < 0.002) | − 5.438 (P < 0.002) |
| Kenya  (n=18) | 4             | 2                           | 6                      | 6    | 1.11 | 6    | 0.647 ± 0.095 | 0.0030 ± 0.0010 | − 0.003 ± 0.006 | − 1.208 (P > 0.1) | − 1.468 (P > 0.1) | − 1.607 (P > 0.1)  |
| Nigeria  (n=32) | 3             | 8                           | 11                     | 11   | 2.98 | 14   | 0.929 ± 0.020 | 0.0030 ± 0.0004 | − 0.012 ± 0.006 | 0.289 (P > 0.1) | − 0.092 (P > 0.1) | 0.031 (P > 0.1)  |
| Thailand (n=10) | 1             | 5                           | 6                      | 6    | 2.69 | 5    | 0.844 ± 0.080 | 0.0030 ± 0.0005 | − 0.008 ± 0.005 | 1.10787 (P > 0.10) | 0.77491 (P > 0.10) | 0.96107 (P > 0.10) |
| K1        |                          |                             |                        |      |      |      |         |        |       |                      |                         |                         |
| Myanmar   | 47                       | 68                          | 119                    | 115  | 33.22| 26   | 0.990 ± 0.013 | 0.0297 ± 0.0019 | − 0.016 ± 0.009 | 0.373 (P > 0.10) | − 1.074 (P > 0.10) | − 0.702 (P > 0.10) |
| Kenya  (n=22) | 11                        | 44                          | 57                     | 55   | 22.75| 6    | 0.736 ± 0.070 | 0.0420 ± 0.0035 | − 0.014 ± 0.014 | 1.805 (0.05 < P < 0.10) | 0.471 (P > 0.10) | 1.031 (P > 0.10)  |
| Nigeria  (n=19) | 8             | 62                          | 74                     | 70   | 26.63| 13   | 0.906 ± 0.060 | 0.0280 ± 0.0034 | − 0.005 ± 0.010 | 1.063 (P > 0.10) | 1.042 (P > 0.10) | 1.220 (P > 0.10)  |
| Thailand (n=40) | 2             | 64                          | 68                     | 66   | 22.80| 10   | 0.810 ± 0.039 | 0.0230 ± 0.0034 | − 0.006 ± 0.008 | 1.540 (P > 0.1) | 1.727 (P < 0.02) | 1.976 (P < 0.02)  |

n number of sequences analysed, S number of Segregating sites, K average number of nucleotide differences, H number of Haplotypes, Hd haplotype diversity, π observed average pairwise nucleotide diversity, dN rate of non-synonymous mutations, dS rate of synonymous mutations, SD standard deviation
consequences of the polymorphism should be considered for development of a vaccine based on PfMSP-3. This study provides in-depth insight into the genetic nature and population structure of global pfmsp-3. Considering that rather few global pfmsp-3 sequences were currently available, further examination of the genetic diversity and evolutionary aspect of pfmsp-3 with more global pfmsp-3 sequences would be necessary to better understand the genetic make-up of pfmsp-3 in the natural P. falciparum population.

**Table 2** Recombination event in Myanmar pfmsp-3

| Allelic type | n  | Ra   | Rb   | Rm |
|-------------|----|------|------|----|
| 3D7         | 43 | 0.0171 | 18.2 | 1  |
| K1          | 29 | 0.0023 | 3.2  | 10 |

**Fig. 6** Nucleotide diversity and test of natural selection in Myanmar pfmsp-3. 

- **a** Sliding window plot presented nucleotide diversity (π) values in Myanmar pfmsp-3. A window size of 10 bp and step size of 5 bp were used.
- **b** Sliding window calculation of Tajima’s D statistic was performed in Myanmar pfmsp-3. A window length of 10 bp and step size of 5 bp were used. Each domain is presented by different color bar on the graphs: alanine heptad repeat domains (black), glutamate rich domain (orange), and leucine zipper domain (green).

**Fig. 7** The linkage disequilibrium (LD) of Myanmar pfmsp-3. The LD plots show non-random associations between nucleotide variations in Myanmar pfmsp-3 at different polymorphic sites. The R² values are plotted against the nucleotide distance with two-tailed Fisher’s exact test of significance.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12936-020-03256-y.

**Additional file 1:** Fig. S1. Map of study site. The blood samples were collected from patients who infected P. falciparum. Community-based survey was conducted in 3 villages in Pyin Oo Lwin, and Naung Cho, Upper Myanmar in 2015.

**Abbreviations**

- AHR: Alanine heptad repeat; dS: Synonymous substitution; dN: Non-synonymous substitution; GLURP: Glutamate rich protein; Hd: Haplotype diversity; K: Average number pair-wise nucleotide difference; PFMSP-3: Plasmodium falciparum merozoite surface protein-3; PCR: Polymerase chain reaction; rRNA: Ribosomal RNA; SPAM: Secreted polymorphic antigen associated with merozoites; S: Segregating sites; UV: Ultraviolet; π: Nucleotide diversity.

**Acknowledgements**

We thank the staffs in the Department of Medical Research Pyin Oo Lwin Branch and the health professionals in Naung Cho and Pyin Oo Lwin townships for their contribution and technical support during blood collection.

**Authors’ contributions**

HGL and TLT performed the genetic analysis of pfmsp-3. JMK, JL, MM, MM, and TSK contributed to blood sample collection. HGL, TLT, JMK, TCV, HN, TSK, HJS, and BKN analysed and interpreted the data. BKN designed and supervised
the experiment. HGL and BKN drafted the manuscript. All authors read and approved the final manuscript.

Funding
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2018M3A9H5055614) and by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (NRF-2019K1A3A9A0100005).

Availability of data and materials
The data supporting the conclusions of this article are provided within the article and its additional files. The original datasets analysed in this current study are available from the corresponding author upon request. The nucleotide sequences reported in this study have been deposited in the GenBank database under the accession numbers MN787860-MN787671.

Ethics approval and consent to participate
This study was approved by the Ethics Review Committee, Department of Medical Research, Myanmar (97/Ethics 2015) and by the Ethical Review Committee of Inha University School of Medicine, Korea (INHA 15-013). Informed written consent and permission were obtained from each individual.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Parasitology and Tropical Medicine, Gyeongsang National University College of Medicine, Jinju 52727, Republic of Korea. 2 BK21Plus Team for Anti-aging Biotechnology and Industry, Department of Convergence Medical Science, Gyeongsang National University, Jinju 52727, Republic of Korea. 3 Department of Tropical Medicine, Inha University College of Medicine, Incheon 22122, Republic of Korea. 4 Department of Medical Research, Pyin Oo Lwin Branch, Pyin Oo Lwin, Myanmar. 5 Department of Microbiology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.

Received: 3 April 2020 Accepted: 8 May 2020
Published online: 19 May 2020

References
1. Pearce JA, Hodder AN, Anders RF. The alanine-rich heptad repeats are intact in the processed form of Plasmodium falciparum MSP3. Exp Parasitol. 2004;108:186–9.
2. Ouevat C, Bouahou-Tayou H, Grass-Masse H, Lepers JP, Balambo-rambo L, Tatar A, et al. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem Inst Oswaldo Cruz. 1994;89:77–80.
3. Imam M, Singh S, Kaushik NK, Chauhan VS. Plasmodium falciparum merozoite surface protein 3: oligomerization, self-assembly, and heme complex formation. J Biol Chem. 2014;289:3856–68.
4. Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, et al. Merozoite surface protein 3 protection against malaria in Aotus nancymai monkeys. J Infect Dis. 2002;185:657–64.
5. Tsai CW, Duggan PF, Jin AJ, Macdonald NJ, Kotova S, Lebowitz J, et al. Characterization of a protective Eschrichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Mol Biochem Parasitol. 2009;164:45–56.
6. Oiser FH, Polley SD, Mwangi T, Lowe B, Conway DJ, Marsh K. Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3. Parasite Immunol. 2007;29:387–94.
7. Druelle P, Sperini F, Soesoe D, Conradin G, Mejia P, Singh S, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005;2:e344.
8. Lusingu JP, Gesase S, Misham S, Francis F, Leminge M, Seth M, et al. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J. 2009;8:163.
9. Jepson MP, Jogdand PS, Singh SK, Esen M, Christiansen M, Issifou S, et al. The malaria vaccine candidate GM2Z elicits functional antibodies in individuals from malaria endemic and non-endemic areas. J Infect Dis. 2013;208:479–88.
10. Esen M, Kremser PG, Schleucher R, Gassler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GM2Z—a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27:6862–8.
11. Mordmüller B, Szywko K, Greutelaers B, Mewono L, Treut C, et al. Safety and immunogenicity of the malaria vaccine candidate GM2Z in malaria-exposed, adult individuals from Lambaréné. Gabon Vaccine. 2010;28:6698.
12. Belard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GM2Z in African children. PLoS ONE. 2011;6:e22525.
13. Paratardoolakot S, Sawaswong V, Simpalipan P, Kaewthamason M, Srinoon N, Haranyahtanakorn P. Genetic diversity of the merozoite surface protein-3 gene in Plasmodium falciparum populations in Thailand. Malar J. 2016;15:517.
14. Ebrahimzadeh A, Mohammadi S, Jamshidi A. Allelic forms of merozoite surface protein-3 in Plasmodium falciparum isolates from southeast of Iran. Jundishapur J Microbiol. 2014;7:e9829.
15. Sawaswong V, Simpalipan P, Srinoon N, Haranyahtanakorn P, Paratardoolakot S. Allelic diversity and geographical distribution of the gene encoding Plasmodium falciparum merozoite surface protein-3 in Thailand. Korean J Parasitol. 2015;53:177–87.
16. Soulamia I, Bigoga JD, Ndialaye M, Bougouma EC, Quagrainie J, Casimiro PN, et al. Genetic diversity of polymorphic vaccine candidate antigens (apical membrane antigen-1, merozoite surface protein-3, and erythrocyte binding antigen-175) in Plasmodium falciparum isolates from western and central Africa. Am J Trop Med Hyg. 2011;84:276–84.
17. Huber W, Felger I, Matile H, Lipps HJ, Steiger S, Beck HP. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol. 1997;87:231–4.
18. McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, Thompson JK, Marshall VM, et al. Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1994;6853–67.
19. McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol. 1997;90:21–31.
20. Burgess BR, Schuck P, Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J Biol Chem. 2005;280:37236–45.
21. Kang JM, Cho PY, Moe M, Lee J, Jun H, Lee HW, et al. Comparison of the diagnostic performance of microscopic examination with nested polymerase chain reaction for optimum malaria diagnosis in Upper Myanmar. Malar J. 2017;16:119.
22. Librado P, Rozas J. DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics. 2009;25:1451–2.
23. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013;30:2725–9.
24. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol. 1986;3:418–26.
25. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics. 1989;123:585–95.
26. Fu YX, Li WH. Statistical tests of neutrality of mutations. Genetics. 1993;133:693.
27. Jordán SJ, Branch OH, Castro JC, Oster RA, Rayner JC. Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hyperendemic transmission environment. Am J Trop Med Hyg. 2009;80:479–86.
28. Okenu DM, Thomas AW, Conway DJ. Allelic lineages of the merozoite surface protein 3 gene in Plasmodium reichenowi and Plasmodium falciparum. Mol Biochem Parasitol. 2000;109:185–8.
29. Gupta S, Maiden MC, Feavers IM, Nee S, May RM, Anderson RM. The maintenance of strain structure in populations of recombinating infectious agents. Nat Med. 1996;2:437–42.
30. WHO. World malaria report 2018. Geneva: World Health Organization; 2018.
31. Lê HG, Kang JM, Jun H, Lee J, Thái TL, Myint MK, et al. Changing pattern of the genetic diversities of Plasmodium falciparum merozoite surface protein-1 and merozoite surface protein-2 in Myanmar isolates. Malar J. 2019;18:241.
32. Lê HG, Kang JM, Moe M, Jun H, Thái TL, Lee J, et al. Genetic polymorphism and natural selection of circumsporozoite surface protein in Plasmodium falciparum field isolates from Myanmar. Malar J. 2018;17:361.
33. Thái TL, Jun H, Lee J, Kang JM, Lê HG, Lin K, et al. Genetic diversity of merozoite surface protein-1 C-terminal 42 kDa of Plasmodium falciparum (PMSP-142) may be greater than previously known in global isolates. Parasit Vectors. 2018;11:455.
34. Kang JM, Lee J, Moe M, Jun H, Lê HG, Kim TI, et al. Population genetic structure and natural selection of Plasmodium falciparum apical membrane antigen-1 in Myanmar isolates. Malar J. 2018;17:71.
35. Deshmukh A, Chourasia BK, Mehrotra S, Kana IH, Paul G, Panda A, et al. Plasmodium falciparum MSP3 exists in a complex on the merozoite surface and generates antibody response during natural infection. Infect Immun. 2018;86:e00067.
36. Gondeau C, Corradin G, Heitz F, Le Peuch C, Balbo A, Schuck P, et al. The C-terminal domain of Plasmodium falciparum merozoite surface protein 3 self-assembles into alpha-helical coiled coil tetramer. Mol Biochem Parasitol. 2009;165:153–61.
37. Rodríguez LE, Curtidor H, Ocampo M, Garcia J, Puentes A, Valbuena J, et al. Identifying Plasmodium falciparum merozoite surface antigen 3 (MSP3) protein peptides that bind specifically to erythrocytes and inhibit merozoite invasion. Protein Sci. 2005;14:1778–86.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions